We are living in a modern world of technology. Gene Therapy is the new generation of the advanced medical sector. Let’s see the potential Gene stocks for investment.
The evolving cutting-edge science has given a new shape to the field of genetics, making impossible things possible. The development of mapping the human genome was the first step of unveiling the mystery behind genetics.
Today’s Gene Therapy firms are working on CRISPR technology. CRISPR is also known as clustered regularly interspaced short palindromic repeats. This technology fancies calculated genetic engineering that helps in the treatment of genetic disorders.
In the past few years, Gene Therapy firms have seen significant growth. The future awaits this market sector to boom, making gene therapy stocks a worthy investment in long-term growth.
Here are the three best gene therapy stocks for investment in the longer run.
CRISPR Therapeutics (CRSP)
CRISPR Therapeutics (CRSP) is one of the leading gene therapy firms and is considered a long-term stock for investors. Two of the firm’s main candidates include CTX001 and CTX110, which makes CRISPR Therapeutics prominent in its respective space.
CTX001 helps in treating patients suffering from transfusion-dependent beta-thalassemia and sickle cell disease. Whereas, CRISPR’s CTX110 candidate is currently under its clinical trials which just obtained positive Phase 1 results in October 2020. CTX110 is being tested in treating patients with refractory non-Hodgkin lymphoma. These two candidates hold the future of the company in gene therapy.
CRISPR Therapeutics stock has soared over 245% since March 11, 2020. The stock has jumped from $43.28 to now trading at $150.49.
The majority of the analysts rate the CRSP stock as a buy. 11 of the Wall Street analysts have rated it as a buy, while 3 have rated it as a hold, and 2 sell ratings.
In the past three months, CRISPR Therapeutics has been published in 12 research reports, showing high interest of analysts towards the stock.
bluebird bio (BLUE)
bluebird bio (BLUE) shares are down by over 50% year-to-date. So, is it still a good buy?
The stock went down after the company faced production problems during the pandemic. bluebird wasn’t able to answer the FDA regarding its commercial manufacturing of a new treatment for sickle cell disease. The company was short on manufacturing capacity.
So, for this reason, bluebird bio (BLUE) will not be able to submit the FDA approval until 2022.
Things have been underwhelming for the gene therapy stock but the long-term growth seems evident. The fact is that the company will still be able to market its sickle cell disease treatment in Europe under the name Zynteglo. Moreover, bluebird has also obtained a priority review from the FDA for its multiple myeloma drug ide-cel. So, the overall portfolio looks good and the stock will have an upward movement in the longer run.
The company dominates the gene therapy market, with Bluebird bio (BLUE) having a market cap of just under $3 billion, pointing towards the long-term valuation for the investors.
bluebird bio has been under analysts’ radar and they have a strong interest in BLUE stock. Wall Street analysts rate bluebird bio stock as a buy.
Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA) consists of a great team with the co-founder Jennifer Doudna, the pioneers of CRISPR technology. In 2012, Doudna was awarded a Nobel Prize in Chemistry for discovering CRISPR technology.
Intellia is working on its lead candidate, NTLA-2001, which is under Phase 1 trials. NTLA-2001 is an in vivo treatment for the genetic disease transthyretin amyloidosis. Moreover, the company has two other lead candidates including NTLA-2002 and NTLA-5001 that are ready for regulatory submission in 2021.
Intellia is well-designed to progress in gene therapy providing solutions to prominent genetic problems.
At the moment, 11 of the Wall Street analysts have passed their rating on NTLA stock, with 7 buy rating and 4 hold rating. So, it’s one gene therapy stock to look at in the long-term run.